Spectrum Pharma (SPPI) Easily Tops Q1 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spectrum Pharmaceuticals (SPPI) PT Bumped to $6 at Jefferies
May 6, 2016 7:56 AM EDTJefferies analyst Chris Howerton bumped his price target on Spectrum Pharmaceuticals (NASDAQ: SPPI) to $6.00 (from $5.00) but maintained a Hold rating following Q1 results.
Howerton commented, "Our takeaways from the call: 1) SPPI commercial team cont. to execute & exp. near-term sales for Evomela (recently launched... More
